Christopher P. Molineaux - Jun 20, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jun 20, 2023
Transactions value $
$23,265
Form type
4
Date filed
6/22/2023, 04:32 PM
Previous filing
Jun 20, 2023
Next filing
Jun 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise $23.3K +16.5K +51.56% $1.41* 48.5K Jun 20, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Stock Option (right to buy) Options Exercise $0 -16.5K -100% $0.00* 0 Jun 20, 2023 Common Stock 16.5K $1.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vested in twelve equal monthly installments commencing July 4, 2020, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.